Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...

Please provide your email address to receive an email when new articles are posted on . A novel bispecific chimeric antigen receptor T-cell therapy appeared safe and effective for younger patients ...

Janux Therapeutics has dosed the first participant in a Phase I clinical trial of JANX011, a Cluster of Differentiation 19 ...

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options. The introduction of CD19 ...

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report The ...

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 ...

SYDNEY & DUARTE, Calif.--(BUSINESS WIRE)--Imugene Ltd (ASX:IMU), an immuno-oncology company and City of Hope, a world-renowned independent cancer research and treatment center near Los Angeles, today ...

Climb Bio (NASDAQ:CLYM) outlined a slate of near-term clinical milestones and its broader autoimmune disease strategy during a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026, wit ...

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial Twenty-five patients were leukapheresed, 24 products were manufactured, and ...

LBCL continues to present major clinical challenges despite improvements with chemoimmunotherapy. Credit: SVStocker via Shutterstock. At the European Society for Medical Oncology (ESMO) Congress, held ...